Developing therapeutic antibodies targeting colorectal cancer.
Innovative pro-cytokine fusion protein platform
Aimed to solve problems of drug metabolism and drug delivery of cytogenic drugs, which can be extended to design other biological macromolecule prodrugs
First novel drug for Amyotrophic lateral sclerosis (ALS) & Frontotemporal dementia (FTD)
Combine genetic and clinical discoveries with stem cell technologies to develop precision therapies for ALS and FTD patients
QureBio was founded in May 2017, focusing on drug R&D for cancer, immunity and inflammation. QureBio committed to developing the next generation of multifunctional cancer therapeutic antibodies, regulating the tumour microenvironment, developing cancer therapeutic and autoimmune antibody pipelines.
Developing innovative treatment of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy.
Hijacks Genes---- Reglagene Takes Them Back
Reglagene creates and develops quadruplex-interactive medicines that selectively speed or slow gene expression rate at the single gene level
First-in-class innovative drug for vascular inflammation
Focus on the progress of endothelial dysfunction
Target non-coding RNA for therapy
developing miRNA-targeting small molecule drugs, and using a fragment-based screening with NMR